PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
96.69%
Cash & equivalents yoy growth at least 1.5x AXSM's 26.11%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
96.69%
Cash + STI yoy ≥ 1.5x AXSM's 26.11%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
119.86%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
94.31%
≥ 1.5x AXSM's 24.70%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-6.34%
Below half AXSM's 0.88%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
Below half of AXSM's 47.78%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
78.33%
≥ 1.5x AXSM's 24.78%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-11.61%
Less than half of AXSM's 78.71%. David Dodd sees a more disciplined AP approach or lower volume.
-42.55%
Less than half of AXSM's 302.23%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
11.61%
Below half of AXSM's 28.57%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
-11.56%
Less than half of AXSM's 69.53%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.36%
1.25-1.5x AXSM's -7.40%. Martin Whitman is wary of heavier future burdens.
No Data
No Data available this quarter, please select a different quarter.
-11.23%
Less than half of AXSM's 14.96%. David Dodd sees far fewer liability expansions relative to competitor.
36.01%
Above 1.5x AXSM's 3.09%. Michael Burry suspects heavy new equity expansion or dilution.
-2.61%
Below half AXSM's -11.64%. Michael Burry suspects major net losses or high dividends vs. competitor.
-6.95%
Less than half of AXSM's 100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
193.87%
Below half AXSM's -859.50%. Michael Burry sees potential underperformance in building shareholder capital.
78.33%
Below half AXSM's -331.11%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-9.95%
Less than half of AXSM's 1.17%. David Dodd sees less overall debt expansion vs. competitor.
-116.79%
Above 1.5x AXSM's -46.85%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.